Indeed, despite the demonstration that distinct immune and mutational profiles are present across the spectrum of angiosarcomas [85] and that tumor mutation burden, PD-L1 overexpression, and an immunogenic tumor microenvironment have been suggested to predict the response to immunotherapy, no study demonstrated the efficacy of any single parameter alone, suggesting that an integrated approach using multiple targets in combination should be used [60,87,88,89,90]. The gene discussed is CD274; the disease is neoplasm.